Publications

The EMBO journal

In situ CRISPR-Cas9 base editing for the development of genetically engineered mouse models of breast cancer.

02-03-2020

Science translational medicine

BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers.

19-02-2020

Nat: Nature

Pan-cancer analysis of whole genomes

05-02-2020

Genes & development

TRPS1 acts as a context-dependent regulator of mammary epithelial cell growth/differentiation and breast cancer development.

01-02-2020

Journal of mammary gland biology and neoplasia

Exogenous ERα Expression in the Mammary Epithelium Decreases Over Time and Does Not Contribute to p53-Deficient Mammary Tumor Formation in Mice.

01-12-2019

Journal of mammary gland biology and neoplasia

GATA3 Truncating Mutations Promote Cistromic Re-Programming In Vitro, but Not Mammary Tumor Formation in Mice.

01-09-2019

Nature communications

Rebalancing of actomyosin contractility enables mammary tumor formation upon loss of E-cadherin.

23-08-2019

Clinical cancer research : an official journal of the American Association for Cancer Research

EZH2 Is Overexpressed in BRCA1-like Breast Tumors and Predictive for Sensitivity to High-Dose Platinum-Based Chemotherapy.

15-07-2019

Cancer discovery

PARP Inhibitor Efficacy Depends on CD8⁺ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer.

01-06-2019

The EMBO journal

Long-term expanding human airway organoids for disease modeling.

15-02-2019

Cancer research

Radiosensitivity Is an Acquired Vulnerability of PARPi-Resistant BRCA1-Deficient Tumors.

01-02-2019

Nature

Author Correction: Landscape of somatic mutations in 560 breast cancer whole-genome sequences.

01-02-2019

Nature communications

Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer.

23-01-2019

Nature communications

The ASCIZ-DYNLL1 axis promotes 53BP1-dependent non-homologous end joining and PARP inhibitor sensitivity.

17-12-2018

EMBO molecular medicine

A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation.

01-12-2018

Cancer metastasis reviews

Cancer-associated fibroblasts as key regulators of the breast cancer tumor microenvironment.

01-12-2018

BMC bioinformatics

XenofilteR: computational deconvolution of mouse and human reads in tumor xenograft sequence data.

04-10-2018

Cancer research

Transcriptomics and Transposon Mutagenesis Identify Multiple Mechanisms of Resistance to the FGFR Inhibitor AZD4547.

01-10-2018

The Journal of pathology

BRCA1-associated mammary tumorigenesis is dependent on estrogen rather than progesterone signaling.

01-09-2018

Cancer cell

The Tandem Duplicator Phenotype Is a Prevalent Genome-Wide Cancer Configuration Driven by Distinct Gene Mutations.

13-08-2018

Nature

The shieldin complex mediates 53BP1-dependent DNA repair.

01-08-2018

The Journal of pathology

αE-catenin is a candidate tumor suppressor for the development of E-cadherin-expressing lobular-type breast cancer.

01-08-2018

Open biology

Mouse models in the era of large human tumour sequencing studies.

01-08-2018

Cancer cell

Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality.

11-06-2018

British journal of cancer

Mps1 inhibitors synergise with low doses of taxanes in promoting tumour cell death by enhancement of errors in cell division.

01-06-2018

Molecular oncology

Haploid genetic screens identify genetic vulnerabilities to microtubule-targeting agents.

01-06-2018

Nucleic acids research

Easy quantification of template-directed CRISPR/Cas9 editing.

01-06-2018

Cell reports

The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient Cells.

15-05-2018

Annals of oncology : official journal of the European Society for Medical Oncology

RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer.

01-05-2018

Cell reports

Multifaceted Impact of MicroRNA 493-5p on Genome-Stabilizing Pathways Induces Platinum and PARP Inhibitor Resistance in BRCA2-Mutated Carcinomas.

03-04-2018

Cancer discovery

E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer.

01-04-2018

Oncogene

Insertional mutagenesis in a HER2-positive breast cancer model reveals ERAS as a driver of cancer and therapy resistance.

01-03-2018

Nature methods

BRCA-deficient mouse mammary tumor organoids to study cancer-drug resistance.

01-02-2018

Laboratory investigation; a journal of technical methods and pathology

Lobular carcinoma in situ and invasive lobular breast cancer are characterized by enhanced expression of transcription factor AP-2β.

01-01-2018

Clinical cancer research : an official journal of the American Association for Cancer Research

Selected Alkylating Agents Can Overcome Drug Tolerance of G₀-like Tumor Cells and Eradicate BRCA1-Deficient Mammary Tumors in Mice.

15-11-2017

Nature cell biology

EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation.

01-11-2017

Cancer research

PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models.

01-11-2017

Oncotarget

Neoadjuvant olaparib targets hypoxia to improve radioresponse in a homologous recombination-proficient breast cancer model.

20-10-2017

EMBO molecular medicine

BRCA1 and BRCA2 tumor suppressors protect against endogenous acetaldehyde toxicity.

01-10-2017

Oncotarget

Intraductal cisplatin treatment in a BRCA-associated breast cancer mouse model attenuates tumor development but leads to systemic tumors in aged female mice.

22-09-2017

Oncotarget

Nuclear receptor NR4A1 is a tumor suppressor down-regulated in triple-negative breast cancer.

15-08-2017

Nature genetics

Insertional mutagenesis identifies drivers of a novel oncogenic pathway in invasive lobular breast carcinoma.

01-08-2017

Nature communications

Progression through mitosis promotes PARP inhibitor-induced cytotoxicity in homologous recombination-deficient cancer cells.

17-07-2017

Nucleic acids research

Identifying transposon insertions and their effects from RNA-sequencing data.

07-07-2017

Oncogene

p53 deficiency induces cancer stem cell pool expansion in a mouse model of triple-negative breast tumors.

27-04-2017

Nature reviews. Cancer

Interrogating open issues in cancer precision medicine with patient-derived xenografts.

01-04-2017

The Journal of pathology

Prophylactic window therapy with the clinical poly(ADP-ribose) polymerase inhibitor olaparib delays BRCA1-deficient mammary tumour formation in mice.

01-03-2017

EMBO molecular medicine

Genetically engineered mouse models in oncology research and cancer medicine.

01-02-2017

Journal of mammary gland biology and neoplasia

p120-Catenin Is Critical for the Development of Invasive Lobular Carcinoma in Mice.

01-12-2016

Nature cell biology

Lgr6 labels a rare population of mammary gland progenitor cells that are able to originate luminal mammary tumours.

01-12-2016